{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T20:40:51Z","timestamp":1780605651443,"version":"3.54.1"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T00:00:00Z","timestamp":1752192000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Heparin-induced thrombocytopenia (HIT) is a rare but potentially life-threatening complication, with an incidence ranging from approximately 0.2%\u20135.0%. The risk of HIT associated with low-molecular-weight heparin (LMWH) is nearly ten times lower than that of unfractionated heparin (UFH). However, LMWH can still induce severe thrombocytopenia and thromboembolic events. This study presents a rare case of LMWH-induced severe type II thrombocytopenia complicated by multiple thromboembolic events. An elderly patient developed HIT following LMWH administration and experienced worsening embolic symptoms after platelet transfusion. The patient received timely discontinuation of heparin analogues and initiation of argatroban therapy with close monitoring of activated partial thromboplastin time (APTT). This was followed by a transition to dabigatran etexilate, which successfully prevented life-threatening embolic complications, limb amputation, and mortality. This case underscores the importance of maintaining a high level of clinical vigilance despite the rarity of LMWH-induced HIT. Once HIT is diagnosed, all forms of heparin should be discontinued immediately, and the decision to administer platelet transfusion should be made with caution to prevent exacerbation of thrombosis. This study provides valuable insights into the early recognition and optimal management of LMWH-induced HIT.<\/jats:p>","DOI":"10.3389\/fphar.2025.1573840","type":"journal-article","created":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T04:10:29Z","timestamp":1752207029000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Low-molecular-weight heparin-induced thrombocytopenia with multisite embolism: successful management with argatroban and dabigatran \u2013 a case report and literature review"],"prefix":"10.3389","volume":"16","author":[{"given":"Huixin","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xitao","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e19","DOI":"10.1016\/j.jtcvs.2015.04.054","article-title":"Rivaroxaban for treatment of heparin-induced thrombocytopenia after cardiac surgery: a case report","volume":"150","author":"Abouchakra","year":"2015","journal-title":"J. Thorac. Cardiovasc Surg."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.13286\/j.1001-5213.2021.12.19","article-title":"Pharmaceutical care for a patient with severe type II thrombocytopenia induced by enoxaparin","volume":"41","author":"Chen","year":"2021","journal-title":"Chin. J. Hosp. Pharm."},{"key":"B3","doi-asserted-by":"publisher","first-page":"161","DOI":"10.3760\/cma.j.issn.1671-0282.2022.02.005","article-title":"Chinese expert consensus on emergency management of adult thrombocytopenia","volume":"31","year":"2022","journal-title":"Chin. J. Emerg. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s11096-021-01260-z","article-title":"Superior outcomes with argatroban for heparin-induced thrombocytopenia: a Bayesian network meta-analysis","volume":"43","author":"Colarossi","year":"2021","journal-title":"Int. J. Clin. Pharm."},{"key":"B5","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1182\/bloodadvances.2018024489","article-title":"American society of hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia","volume":"2","author":"Cuker","year":"2018","journal-title":"Blood Adv."},{"key":"B6","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.artd.2015.07.003","article-title":"Spontaneous heparin-induced thrombocytopenia presenting as bilateral adrenal hemorrhages and pulmonary embolism after total knee arthroplasty","volume":"1","author":"Elshoury","year":"2015","journal-title":"Arthroplast Today"},{"key":"B7","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s13054-021-03581-x","article-title":"Argatroban versus heparin in patients without heparin-induced thrombocytopenia during venovenous extracorporeal membrane oxygenation: a propensity-score matched study","volume":"25","author":"Fisser","year":"2021","journal-title":"Crit. Care"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1182\/blood-2014-10-605493","article-title":"Platelet transfusions in platelet consumptive disorders are associated with arterial thrombosis and in-hospital mortality","volume":"125","author":"Goel","year":"2015","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.accpm.2020.03.012","article-title":"Diagnosis and management of heparin-induced thrombocytopenia","volume":"39","author":"Gruel","year":"2020","journal-title":"Anaesth. Crit. Care Pain Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.7501\/j.issn.1674-6376.2021.10.006","article-title":"Research progress on pharmacological effects and clinical applications of argatroban","volume":"44","author":"Han","year":"2021","journal-title":"Drug Eval. Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"64s","DOI":"10.1378\/chest.119.1_suppl.64s","article-title":"Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety","volume":"119","author":"Hirsh","year":"2001","journal-title":"Chest"},{"key":"B12","doi-asserted-by":"publisher","first-page":"509","DOI":"10.5694\/mja2.50213","article-title":"Diagnosis and management of heparin-induced thrombocytopenia: a consensus statement from the thrombosis and haemostasis society of Australia and New Zealand HIT writing group","volume":"210","author":"Joseph","year":"2019","journal-title":"Med. J. Aust."},{"key":"B13","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report","volume":"149","author":"Kearon","year":"2016","journal-title":"Chest"},{"key":"B14","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1097\/aln.0000000000004090","article-title":"Heparin-induced thrombocytopenia: perioperative diagnosis and management","volume":"136","author":"Koster","year":"2022","journal-title":"Anesthesiology"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1111\/jth.13330","article-title":"Rivaroxaban for treatment of suspected or confirmed heparin-induced thrombocytopenia study","volume":"14","author":"Linkins","year":"2016","journal-title":"J. Thromb. Haemost."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.11855\/j.issn.0577-7402","article-title":"Committee of thrombosis and hemostasis in critical illness, China medicine education association 2022. Chinese expert consensus on the diagnosis and treatment of anticoagulant-related bleeding","volume":"47","author":"Liu","year":"2022","journal-title":"Med. J. Chin. People's Liberation Army"},{"key":"B17","doi-asserted-by":"publisher","first-page":"119","DOI":"10.13498\/j.cnki.chin.j.ecc.2023.02.13","article-title":"Anticoagulation management in patients with heparin-induced thrombocytopenia during cardiopulmonary bypass and extracorporeal membrane oxygenation","volume":"21","author":"Li","year":"2023","journal-title":"Chin. J. Extracorpor. Circulation"},{"key":"B18","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.tmrv.2019.08.001","article-title":"The use of flow cytometry in the diagnosis of heparin-induced thrombocytopenia (HIT)","volume":"34","author":"Mali\u010dev","year":"2020","journal-title":"Transfus. Med. Rev."},{"key":"B19","doi-asserted-by":"publisher","first-page":"14","DOI":"10.2450\/2020.0248-20","article-title":"Heparin induced thrombocytopenia: position paper from the Italian society on thrombosis and haemostasis (SISET)","volume":"19","author":"Marcucci","year":"2021","journal-title":"Blood Transfus."},{"key":"B20","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1182\/hematology.2024000566","article-title":"Practical guide to the diagnosis and management of heparin-induced thrombocytopenia","volume":"2024","author":"May","year":"2024","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"B21","doi-asserted-by":"publisher","first-page":"8217","DOI":"10.3390\/ijms24098217","article-title":"Novel knowledge about molecular mechanisms of heparin-induced thrombocytopenia type II and treatment targets","volume":"24","author":"Mongirdien\u0117","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B22","doi-asserted-by":"publisher","first-page":"5184","DOI":"10.1182\/bloodadvances.2020002963","article-title":"Management of heparin-induced thrombocytopenia: systematic reviews and meta-analyses","volume":"4","author":"Morgan","year":"2020","journal-title":"Blood Adv."},{"key":"B23","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1182\/blood-2015-07-661215","article-title":"Diagnostic value of immunoassays for heparin-induced thrombocytopenia: a systematic review and meta-analysis","volume":"127","author":"Nagler","year":"2016","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1002\/jcph.1300","article-title":"Dabigatran as a treatment option for heparin-induced thrombocytopenia","volume":"59","author":"Nasiripour","year":"2019","journal-title":"J. Clin. Pharmacol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"829","DOI":"10.19803\/j.1672-8629.20240054","article-title":"Mechanisms and diagnosis of drug-induced thrombocytopenia","volume":"21","author":"Nie","year":"2024","journal-title":"Chin. J. Drug Alert"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1111\/jth.14575","article-title":"Heparin-induced thrombocytopenia complicating extracorporeal membrane oxygenation support: review of the literature and alternative anticoagulants","volume":"17","author":"Pollak","year":"2019","journal-title":"J. Thromb. Haemost."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2953","DOI":"10.1111\/jth.15901","article-title":"Coagulation assays and direct oral anticoagulant levels among patients having an elective surgery or procedure","volume":"20","author":"Shaw","year":"2022","journal-title":"J. Thromb. Haemost."},{"key":"B28","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1007\/s11239-016-1365-0","article-title":"Novel oral anticoagulants for heparin-induced thrombocytopenia","volume":"42","author":"Skelley","year":"2016","journal-title":"J. Thromb. Thrombolysis"},{"key":"B29","doi-asserted-by":"publisher","first-page":"837629","DOI":"10.3389\/fimmu.2022.837629","article-title":"Immune-mediated platelet activation in COVID-19 and vaccine-induced immune thrombotic thrombocytopenia","volume":"13","author":"Uzun","year":"2022","journal-title":"Front. Immunol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1182\/blood-2017-04-778993","article-title":"Direct oral anticoagulants for treatment of HIT: update of Hamilton experience and literature review","volume":"130","author":"Warkentin","year":"2017","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","first-page":"113","DOI":"10.19347\/j.cnki.2096-1413.202136036","article-title":"Clinical diagnostic efficacy of heparin-induced thrombocytopenia (HIT) antibodies in pregnant patients with HIT","volume":"6","author":"Xu","year":"2021","journal-title":"Clin. Res. Pract."},{"key":"B32","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3969\/j.issn.1000-3614.2018.zc.028","article-title":"Interpretation of the Chinese expert consensus on heparin-induced thrombocytopenia","volume":"33","author":"Xu","year":"2018","journal-title":"Chin. Circulation J."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1573840\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T04:10:36Z","timestamp":1752207036000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1573840\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,11]]},"references-count":32,"alternative-id":["10.3389\/fphar.2025.1573840"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1573840","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,11]]},"article-number":"1573840"}}